April 2026 Research Update

This month added several early pieces about glucocorticoids (cortisol-like medicines) in CAH and related adrenal conditions: how to lower higher-than-needed doses when starting a newer medicine, how long-term cortisol exposure might be measured, and how different dosing levels may show up in blood signals. Taken together, these studies do not prove one best approach, but they make it clearer that researchers are trying to measure cortisol exposure more directly and make dose changes safer and more trackable. The evidence ranges from expert guidance and observational biomarker work to single-patient reports, so the findings are more about direction than final answers. [1] [2] [3] [4]

One expert panel described a gradual way to reduce supraphysiologic glucocorticoid doses in adults with classic CAH after starting crinecerfont (a CRF1 receptor antagonist intended to lower ACTH and adrenal androgens). The panel emphasized tapering slowly to avoid withdrawal or adrenal insufficiency and aiming to keep androgen control while maintaining needed cortisol replacement. They also discussed practical steps like switching from longer-acting glucocorticoids to shorter-acting ones and adjusting timing to better match normal daily cortisol patterns. [1]

A separate study in adults with hydrocortisone-treated adrenal insufficiency (not limited to CAH) reported that hair cortisol concentration was higher in treated patients than in healthy controls, and differed by adrenal insufficiency subtype. Hair cortisol also correlated with hydrocortisone dose and with measures like body size and blood pressure, and it separated undertreated from overtreated groups in this dataset. This supports the idea that a hair sample could reflect longer-term cortisol exposure, but the authors noted that prospective studies are still needed before it can guide dose optimization. [2]

Two early studies looked for biological signals that might mirror glucocorticoid exposure patterns. In a small group of people with classic CAH due to 21-hydroxylase deficiency, higher glucocorticoid doses were linked to lower levels of seven circulating microRNAs (small RNA markers measured in blood), while no differences were seen between short-acting and long-acting glucocorticoid types. In a single long follow-up case, a boy with CAH who had osteopenia on prior therapy received continuous subcutaneous hydrocortisone pump delivery designed to mimic circadian cortisol patterns, with reported long-term stabilization and later normalization of bone density alongside biochemical control. [3] [4]

For patients and caregivers, the main update is that researchers are trying to make glucocorticoid management more measurable and more personalized, especially when new medicines like crinecerfont are added. The crinecerfont paper is expert guidance rather than trial results, so it describes a careful approach but does not report patient outcomes. Hair cortisol and microRNA work may matter later if confirmed, because they point to possible ways to track long-term glucocorticoid exposure with a lab measure rather than only symptoms and single blood tests. The hydrocortisone pump report is one person and cannot predict what most people will experience, but it highlights the long-standing research goal of matching the body's daily cortisol rhythm and tracking long-term effects like bone health. [1] [2] [3] [4]

This month, studies looking at diagnosis and risk showed a consistent message: CAH can be missed or misunderstood unless testing is matched to the right situation, and genetics plus hormone testing can add clarity. Some work focused on when screening tests do or do not pick up non-classic CAH, while other work showed that genotype can relate to hormone responses and that newer sequencing can resolve confusing genetic results. The overall picture became clearer that diagnostic certainty often depends on combining clinical signs with targeted lab and genetic testing rather than relying on one test alone. [5] [6] [7] [8] [9] [10]

In pediatric non-classic CAH (NCCAH), one center reported that most affected children had neonatal 17-OHP screening values below recall thresholds, meaning newborn screening often did not flag them. Within the NCCAH group, higher 17-OHP levels at diagnosis were linked to earlier symptom onset and to higher hydrocortisone doses in routine care, and bone age advancement was reported in all patients. This helps explain why some families only get answers later, and why severity can look different across children even within the same broad diagnosis. [5]

In contrast, a study of 210 adolescent and adult women evaluated for hyperandrogenism and/or infrequent ovulation found no cases of non-classic CAH when ACTH stimulation testing was used, and they reported no false negatives from basal 17-OHP screening in that specific population. Basal 17-OHP was higher in people with PCOS but still stayed below the study's 2 ng/mL threshold, and it tracked with PCOS-related hormone and ultrasound markers. In plain terms, this dataset suggests that broad ACTH testing in that referral population may not find many additional CAH cases, though it does not address every clinical setting or family history scenario. [6]

Several studies added detail on how genetics can refine diagnosis and anticipate hormone responses. In 23 children with NCCAH, those with a mild/severe CYP21A2 genotype had lower peak cortisol on ACTH testing and more frequent adrenal insufficiency than those with mild/mild genotypes, suggesting genotype may give a clue to cortisol reserve in some patients. In infertility genetics, long-read sequencing in 722 infertile men added diagnostic yield compared with standard testing and helped clarify how CYP21A2 variants were arranged (cis/trans), which can change how results are interpreted. [7] [8]

Two case-based papers illustrated how complex testing can resolve PCOS-like presentations and uncommon variant patterns. In two females with suspected non-classic CAH, mass spectrometry steroid profiling showed elevated 17-hydroxyprogesterone with otherwise reassuring cortisol-related markers, and genetic testing identified distinct CYP21A2 variant patterns that required careful interpretation. Another case report in a girl with amenorrhea and hyperandrogenism identified compound heterozygous CYP21A2 mutations, including an exons 1-3 ins/del variant thought to cause loss of gene function, with PCOS specifically excluded in the workup. [9] [10]

For patients, these studies mainly add understanding about why CAH (especially non-classic CAH) can be difficult to confirm and why different tests may be used in different situations. The pediatric NCCAH data show that newborn screening numbers can look normal even when NCCAH is later diagnosed, while the hyperandrogenism referral study shows that in one large clinic population ACTH stimulation testing did not uncover hidden NCAH cases beyond basal screening. The genetics studies suggest that the exact CYP21A2 variant pattern can matter for interpreting results and may relate to cortisol response in some children, but the evidence is still early and based on limited samples or specific populations. This information may matter more over time as testing strategies and genetic interpretation become more standardized. [5] [6] [7] [8] [9] [10]

This month combined broader quality-of-life research with several individual cases showing the range of real-world CAH experiences, from fatigue and puberty-related concerns to fertility issues and rare complications. The quality-of-life studies reinforced that CAH affects daily life well beyond hormone numbers, including emotional wellbeing, relationships, and family strain. The case reports and small case series added concrete examples of diagnostic complexity and long-term complications that can occur in some people, but they cannot show how common these experiences are. [11] [12] [13] [14] [15] [16] [17] [18] [19]

In interviews with adults with CAH and a few family members, participants described a wide impact on physical, psychological, and social wellbeing, including trauma linked to childhood examinations, body image concerns, sexual dysfunction, fertility worries, and complicated family dynamics. A separate study looking at parents of children with chronic genetic conditions (including CAH) found that frequent emergency department visits and having a child with Duchenne muscular dystrophy predicted lower parent quality of life, while higher income was associated with higher quality of life. Together, these studies underline that daily burdens can come from both medical experiences and the practical demands of ongoing care. [11] [13]

In a small pediatric review (30 children with CAH), better reported quality-of-life prognosis aligned with higher treatment compliance and better hormone control, while the poorer prognosis group had more complications such as high blood pressure and skin darkening. The salt-wasting form was more common in the poorer prognosis group, and hydrocortisone doses were higher in that group in routine care. This does not prove what causes better outcomes, but it describes a pattern where more severe disease and more complications tend to cluster together. [12]

The case reports and case series highlighted how CAH can present and what complications may appear. One adult man with non-classic 21-hydroxylase deficiency had fatigue along with adrenal thickening and multiple lesions on imaging, and hydrocortisone treatment was reported to relieve fatigue and lower 17-OHP. Two reports involving 11beta-hydroxylase deficiency described testicular adrenal rest tumors with fertility or testicular function concerns, and one adult case also included a Leydig cell tumor; steroid treatment plus eplerenone was reported to normalize blood pressure and electrolytes, and ultrasound was emphasized as a follow-up tool in the child. [14] [15] [16]

Other individual reports focused on diagnostic boundaries and rare courses. A case series of three 46,XY siblings with a homozygous CYP17A1 mutation described an initial diagnosis that was later reconsidered based on preserved cortisol levels, and the family underwent gonadectomy with plans for estrogen replacement at puberty, with attention to culturally sensitive support. A forensic case report described a woman with treated CAH who had severe vomiting and diarrhea and died rapidly, with norovirus detected on postmortem molecular testing as a likely contributor to deterioration. One infant case report was included because CAH was part of the differential diagnosis: severe electrolyte disturbances were ultimately explained by secondary pseudohypoaldosteronism tied to urinary tract obstruction and infection, and the child improved after medical stabilization and stepwise surgery. [17] [18] [19]

For patients and caregivers, the biggest practical message is that quality of life in CAH is shaped by medical experiences, body changes, fertility and sexual health concerns, and family pressures, not just lab results. The interview study gives language for issues many people recognize but that are not always captured by standard questionnaires, and it argues that CAH-specific quality-of-life measures are needed. The pediatric prognosis review and the parent quality-of-life study point to factors linked with worse daily impact (such as more complications or frequent emergency visits), but they do not show how to prevent those outcomes. The case reports are mainly useful for awareness that CAH can have diverse presentations and occasional serious courses, while also showing that other conditions can look similar during evaluation. [11] [12] [13] [14] [15] [16] [17] [18] [19]